Navigation Links
ATS Medical Announces Participation in the International Society for Minimally Invasive Cardiothoracic Surgery Meeting
Date:6/3/2009

MINNEAPOLIS, June 3 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Meeting in San Francisco on June 3-6, 2009. The ISMICS meeting is a significant gathering of cardiovascular surgeons from around the world whose interests include the latest developments in less invasive forms of heart surgery. The annual ISMICS meeting provides an excellent venue for the Company to exhibit its growing portfolio of clinically relevant products designed to meet the needs of cardiac surgeons.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Exemplifying ATS's broad product offering is the ATS CryoMaze(R) Surgical Ablation System which is used to treat patients with cardiac arrhythmias. The ATS CryoMaze System provides results comparable to the gold standard cut-and-sew Cox Maze III procedure and is being used by a growing number of surgeons as their ablation technology of choice. ATS is sponsoring a Frontiers in Cryoablation symposium titled "Evolving Standards in Cardiac Arrhythmia Surgery" scheduled at 12:00 pm on Thursday, June 4, 2009 at the Westin St. Francis Hotel. The presentations will include "Rationale for a Complete Cox Maze III Biatrial Lesion Set" by Niv Ad, MD, "Robotic Stand-alone Atrial Fibrillation Surgery: the ECU Experience" by W. Randolph Chitwood, MD, "Minimally Invasive Stand-alone Atrial Fibrillation Surgery: the INOVA Experience" by Niv Ad, MD, and "Ablation of the Ganglionated Plexi: Fact or Fiction?" by Ralph Damiano, MD. The ATS CryoMaze Surgical Ablation System is uniquely suited for robotic and minimally invasive surgical approaches and will be prominently featured in the exhibition.

The ATS Simulus(R) Annuloplasty product line, designed for the heart valve repair market, will be showcased with special focus on the new ATS Simulus Semi-Rigid Annuloplasty Ring. The Simulus products easily accommodate the use of surgical clips during minimally invasive and robotic procedures and are the annuloplasty product of choice for many surgeons using these techniques for mitral valve repair. ATS Medical also offers unique tools designed to meet the access challenges of less invasive and robotic procedures. These tools include the ATS Thoracic Ports which provide excellent visibility and a clear, stable opening for instrument exchange and suture passage and ATS Suture Hooks which facilitate quick and easy running sutures quick and easy.

Another feature of the ATS exhibition will be the ATS 3f(R) Aortic Bioprosthesis which is designed to replace the patient's diseased valve. The ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve with its tubular design that restores continuity between the annulus and the sinotubular junction. By restoring this continuity, the ATS 3f Aortic Bioprosthesis is the only aortic valve that preserves the sinuses and restores native valve stress distribution and physiologic blood flow. The ATS 3f Aortic Bioprosthesis design provides surgeons and patients with a potentially more durable solution to aortic valve replacement.

The mechanical heart valve segment will feature the flagship ATS Open Pivot(R) Heart Valve and its newest advancement, the ATS Open Pivot(R) AP360(TM) with enhanced surgical implant characteristics. The family of ATS mechanical heart valves features a unique open pivot design that results in exceptional hemodynamic performance and a low risk profile.

Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #201.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology: